Evogene (EVGN)
(Delayed Data from NSDQ)
$2.70 USD
+0.01 (0.37%)
Updated Sep 20, 2024 03:58 PM ET
After-Market: $2.69 -0.01 (-0.37%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
EVGN 2.70 +0.01(0.37%)
Will EVGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for EVGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EVGN
Evogene (EVGN) Reports Q4 Loss, Misses Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
EVGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates
Here's Why Evogene (EVGN) is a Great Momentum Stock to Buy
Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?
Other News for EVGN
Evogene files to sell 3.38M ordinary shares for holders
Evogene Announces Major Management Restructuring
Evogene Ltd. Reports Mid-Year Financial Dip
Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement
Evogene prices $5.5M direct offering